<SEC-DOCUMENT>0001193125-12-049286.txt : 20120209
<SEC-HEADER>0001193125-12-049286.hdr.sgml : 20120209
<ACCEPTANCE-DATETIME>20120209161459
ACCESSION NUMBER:		0001193125-12-049286
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120209
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120209
DATE AS OF CHANGE:		20120209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD RESEARCH CORP
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		12587345

	BUSINESS ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d298419d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): February&nbsp;9, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Arrowhead Research Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21898
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>46-0408024</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>225 South Lake Avenue, Suite 300, Pasadena, CA 91101 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (626)&nbsp;304-3400 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4 (c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02 Results of Operations and Financial Condition </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;9, 2012, Arrowhead Research Corporation announced and commented on its fiscal 2012 first quarter financial results for the period ended
December&nbsp;31, 2011. A copy of the press release is furnished herewith as Exhibit&nbsp;99.1 and incorporated by reference herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In
accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit&nbsp;99.1, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or
after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated February 9, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: February&nbsp;9, 2012 </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARROWHEAD RESEARCH CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kenneth Myszkowski</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth Myszkowski</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d298419dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g298419g47s85.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;9, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact:</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Michael Levitan</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Trout Group, LLC</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">646-378-2920</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ir@arrowres.com</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Arrowhead Reports Fiscal 2012 First Quarter Financial Results </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PASADENA, Calif. &#151; February&nbsp;9, 2012 &#151; Arrowhead Research Corporation (NASDAQ: ARWR),</B> a nanomedicine company with development
programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The
first quarter of fiscal 2012 saw transformational change for Arrowhead,&#148; said Dr.&nbsp;Christopher Anzalone, President and Chief Executive Officer.&nbsp;&#147;With the acquisition of the Roche&#146;s RNAi assets and facility, we now have a more
complete set of capabilities to advance our own RNAi therapeutic pipeline products and are positioned as a more attractive partner to larger companies interested in this area. We have also made important progress on our obesity program which has
been cleared by the FDA to initiate human clinical trials.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fiscal 2012 First Quarter and Recent Company Highlights </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pipeline Highlights </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquired Roche&#146;s RNAi assets including Dynamic Polyconjugate (DPC) delivery technology, select licenses and state-of-the-art research facility;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Published a white paper on the effectiveness and safety of Dynamic Polyconjugates&#153;, one of the technologies acquired from Roche;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reported results using Adipotide&#153; that demonstrated substantial weight loss and reduction in body mass index and abdominal circumference in obese
rhesus monkeys in the prominent peer-reviewed journal, <I>Science Translational Medicine</I>; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Received FDA clearance to initiate an Adipotide Phase I clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executed a collaboration and joint licensing agreement with Alnylam, a leading RNAi therapeutics company, which allows Arrowhead to develop a
DPC-enabled RNAi therapeutic candidate targeting hepatitis B virus (HBV) and allows Anlylam to utilize DPC delivery technology for one RNAi therapeutic product. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Highlights </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Received $1.5 million from the issuance of Common Stock and a further $0.5 million from the sale of an investment; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recorded an additional $3.9 million in subscriptions receivable from announced financings over the next several months; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Established an equity line of credit with Lincoln Park Capital to provide financing of up to $15 million that may be drawn down over three years, as
needed; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Implemented a 1-for-10 reverse stock split to decrease the number of common shares outstanding and regain compliance with Nasdaq continued listing
standards. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Appointments </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bruce Given, M.D., as Chief Operating Officer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brendan P. Rae, Ph.D., J.D., as Chief Business Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Lewis, Ph.D., as Vice President of Biology; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Rozema, Ph.D., as Vice President of Chemistry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Perry, DVM, Ph.D. to Board of Directors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Selected Fiscal 2012 First Quarter Financial Results </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the added costs associated
with the research facility we acquired from Roche and its people and research programs, operating expenses increased significantly during the quarter ended December&nbsp;31, 2011. The Company anticipates these costs will increase throughout fiscal
2012 as research and development efforts are accelerated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the quarter ended December&nbsp;31, 2011, Arrowhead reported revenues of
$23,958, compared to revenue of $296,139 in the quarter ended December&nbsp;31, 2010. Total operating expenses for the quarter ended December&nbsp;31, 2011 were $4.1 million, compared to $3.6 million during the quarter ended December&nbsp;31, 2010.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss attributable to Arrowhead for the quarter ended December&nbsp;31, 2011 was $2.5 million, or $0.25 per share based on 10,121,069
weighted average shares outstanding. This compares with a net loss attributable to Arrowhead of $1.4 million, or $0.20 per share based on 7,177,941 weighted average shares outstanding, for the quarter ended December&nbsp;31, 2010. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s net cash used in operations for the quarter ended December&nbsp;31, 2011 was $2.7
million, compared with $0.9 million for the quarter ended December&nbsp;31, 2010. Cash provided by investing activities was $0.5 million, primarily due to cash received from the sale of investments. Cash provided by financing activities was $1.4
million, primarily due to the issuance of Arrowhead common stock. As of December&nbsp;31, 2011, Arrowhead had cash and cash equivalents of $6.8 million and stockholders&#146; equity of $15.7 million. Arrowhead expects to collect an additional $3.9
million in subscriptions receivable from announced financings over the next several months. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conference Call</B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management will host a conference call today, Thursday, February&nbsp;9, 2012 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the
conference call, please dial 877-317-6789 (toll free from the US and Canada), or 412-317-6789 (for international callers). Investors may also access a live audio webcast of this conference call on the Company&#146;s website at
www.arrowheadresearch.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A replay of the webcast will be available approximately two hours after the conclusion of the call. The webcast
archive will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be made available until Thursday, February&nbsp;16, 2012. The audio replay can be accessed by dialing
877-344-7529 (toll free from the US and Canada), or 412-317-0088 (for international callers) and entering Event ID 10009858. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About
Arrowhead Research Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead Research Corporation is a clinical stage nanomedicine company developing
innovative therapies at the interface of biology and nanoengineering. Arrowhead&#146;s world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop
therapeutic agents for a wide range of diseases. The company&#146;s lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and Adipotide</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, an anti-obesity peptide that targets and kills the blood vessels
that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic PolyConjugate</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> (DPC), Liposomal Nanoparticle (LNP), and RONDEL</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies. For more
information, please visit <U>www.arrowheadresearch.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement under the Private Securities Litigation Reform Act:
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This news release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as
a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights.
Arrowhead Research Corporation&#146;s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We
assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"># # #
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g298419g47s85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g298419g47s85.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.0!X`P$1``(1`0,1`?_$`+8```$#!0$!`0``````
M```````&!P@!`@0)"@4#"P$``00#`0````````````````$"!`4#!@<($```
M!@("``0"!@@""P$````!`@,$!08'"``1(1(3"3$546%QD10702*S=#46-G8C
M-_#!,D)BLL(SM+6V&!$``@$#`@0"!P,("`<``````0(#`!$$(04Q01(&41-A
M<8&1(C('L<$4\*%"4G*R(S/APG,T=!4U-M&B@[.T=1;_V@`,`P$``A$#$0`_
M`._CA11PHHX44<**.%%4$0#KOOQ'H.@[_0(^/T!X<*0FW(TPVQ.<ZU@7&TK<
MYEXP+)&$T95XEX_C6:LW8'"9P:MD$I*3B?Q3=K_WW7I*"JFV3.<I3"``..:5
M8%#.0`?&M3[W[IA[/[>FW66WG6Z8UYLY!L`"1>UKZ7]5:;*!NY<JKD!"XSUK
MD+!'R,@W"TPSFUU%TT=Q9S>FX*PC"R$>@T=,6YA.W]-9`!4(7U3&+YNZD9UI
MB4-UYVU^^O(O;OU>[NVW>USMT?*DVZ28]<;\+<=!Y"\+\0Y\*WSU*RPEQ@XV
MTUF68S5>GF#62B9*-=MG[-TT<D]0BJ+MFJNU6#L?*84SF*!BB'?8<O2RO&K#
MF.->V-NR\3/Q8\["8-CS1JX\0&\?B.OB+"QI3<94^CA11PHHX44<**.%%'"B
MCA11PHHX44<**^*Q@*4!'OH3=>`"/7ZIA$>@['P`.*!?7PUI"#TGAT@:\3I[
M*YP-Q-CK7FO+KR/J<5MW"TBH.G%8KL76-<J99JQ8I5N_5:O+DS=Y#C'+X%)U
M4Y$T%#)MRE:D)\`,8>:ANLT^7EB,>8L*GD%_K`UP?OE=R[JWA((6W*+!C'2J
M+!&8^K]>\J-KRT`-J>O/>G5RQ5KE4LB,L@99F[;54#O\D1U/P_@:Q6^8:V=V
MU.T*2NGK!(]$]`%0&JH1ZJYUTSG6$#`7DJ;;BF+U*\G4?!4)]O2!6;>/INN/
MM$69%++^-5!YI$&,[,#RZ6AL+>*V)IQO;;V,G%)!Y@.YQVQ3X7B;^P46U9:P
M[$X_A8Q%H@F>2IK5>GLV\(V3.4%'K4%DT0[]4A1,82@,C:)I`K0Y#N2+6ZA;
MQX5LOT_FR<"`[/E',E4F\320I&`O$CX+`>JU;DP'OEY73JKPHHX44<**.%%'
M"BCA11PHHX44<**M,8"AV/?78!X!W\>*`3H*0L%U/#V#[:TV>[/O1BK!=()K
MK(9+N=#R/EB!/(/IC'=1CKK/5:A`\_!/#.VKR\T7Y(YMYDUFC1<CE54$4G!@
M3#]0_)";3G9\7\`,(BUNH6`]5R16G=U=QX&V(,&5W&2Z]5D%R%'B0RZDVMJ:
MC-[1F`X'*<X;:AEEK.-[H5*DI:M4F'R36EJ7%3EO001;R%C9)-,K7Y.?CZPD
MNJV*59)!(KX_93'%`P!!DVA-NR+3L3*1IJIU]A.M1>TE.1$VY":=H?U65A[N
MIV!]E=#KUHW?M5V;E(JS1VV6:N$#")2JMW*1D5T3"7]8"J(G$!$![Z'B](*_
MI6'(<:W@CS#9C_#9:Y$MW,?US1#/[)E.[([,U./G'?YD8A?PV/T;M`,F#&;]
M=.`1L,MG.MFF9&GO2HHNDUF"'G041$Q#D4\PIC;$^:X:%[Z\"0"*Y;OF4.WL
MY1/DY()^-#9.CIOJ+EP;CGI:NC_2G;S&NY&%(O)V/YMS).8YV:JW5C*1+6O3
MD5;8MNC^./(5UK-6!*(:322A'S,A7KD@MER@"AC%.`3<G!DP'\N;YCSO<?FK
M>MEWW`WG#&7BR`KH"#;J!](4D"_+VU+X![Y'J\O?APJO"BCA11PHHX44<**.
M%%'"BCA129N<TO6JG9+&UC'<VXK\#,SB,+'AW(3*L3&.Y`D4P`?`7L@9N"27
M?AYSAQT:"29(BP56<`GUU'RYGQ\27(1/,*1LW3>U["]AH=;VK\R#.?NFSVP&
M5;AES*>LNL%FNMMDC*2$A98G-:\NV91Y0CHB$="PSI%1Z0P,8W2:^5NS:)^=
M,Q_2(8Q@YZ>V?Z?8$6W1O%//Y+`$]++Q/K!]/*O#V_=\[]NN[39F5A87GB2P
MZHY&/2N@_2`X>^MHWMK>^;M38=A-1-/(>G:VT3!]GR;2<5_RS2,<6&-?1=5F
M9(R+U*$DI#(,LH254%8ZHNG)'2JJQS**>H<PF'7>Z_IULV!MF7O:OD2311=2
MAF4_%X\![O"M\[&^I_>&7O>'L4D.*-L>0*P2(J0#SOU'\N==LV<;=*X\PMF#
M(,"+3YW1<79`N4,602.YC_FM8J<M-QP/6Y%D#K,Q=L2`J0#E$Y.P[#X\X/MB
MIEY\6-(;>9(JFW$*S`>\7KTWNCR86W9&=CG^)%!(R@BXNJ$BP]E?G69]]]/8
MK;"KUNM[%8@U,RC"UN3&P5]O*8WO48YA9APP.R<NHZ3KV6X>302>-5Q(LEZP
MHK`4@G(8Q""7TOM_TQV[`49&'-DQ%]&(9;-:QTN#X\Z\:[S]4N\-V5<7<,;!
ME6,GIZHY`1<V/R.G(>D5,;V4/<QML7O#C'`]*U\PI4*?L=-C4,@-<2QV3VDW
MY(>"G9>$MQPM^4+M$$:U)=-0[LX,R*G9*J%]4O10&A[X[)PL;99MRER9'EB%
MT$A'M`Z5''3VV-;;]+.]-[?NJ/;VP\==NG7I?RE<6/Z)/6[Z`WX6]M=\*8_'
M](>'0A\!^SZ.N>?DN$L>1->KOB#%"+`</;7UXZEHX44<**.%%82\BS;+-VZ[
MENBN[.9-HBLNDBJ[5*05#I-4U#E.X4(F'F$I`,(!X\8S6#V!)1;FPY6I+K\-
MR!U&PN:R05*/70#XCUWX"'V]AX?#C5F1B+<"H/OK)T,./&KO,`?'P\>OCS(6
M4<Q6->IN56"KT;R^41^L!#C2S6)"DD#WTI(!`-[^K[ZQG;UJU1]5XL@U1%1-
M,%7*Z*"8JJF]-),%%SD)ZBBA@*4.^S"/0<4J38]))T.G(_T>-,\Q.F[$!6N-
M=+\OS^%1`L/M[:(W*?E[9:]-M8K#9+$_=2\[.S6$,>R$O,2;U0574C(OW,"=
M=X^=JB)U5#B)SG$1$1'L1M8]^WJ("%,K(4#@%D:P'L(JCD[8[>F<S'"QV)U-
MT%R>=9%1T"T<H5H@+M1M0-;:?<*I*-9NLVFM89H4'8*_,LC^=G*0\M'0:#Z/
M?-3CVFJD<AR#\!X3[WO,B-#/DY$D!74,[$$>%B3^>G8O;FQ0RIDXV'#%.AN"
MJ!2/;;6I0V1M`RD+)0MG0BGD!.,G4%+QTX#52)F(^71-'/(E^W>A^&>-I)NY
M,B=$_8*E.)!`>^N4L<@,B2P_#(3<$`W'3KR_-5UDHK1F.2WE.MC?AKI;VU"A
MW[=WMK1`)IR6F>GD0!B](%D,*8K8@H0@%`02!S!(^H"?8=]=]=AR]7?^X/*Z
MX\O*,1-QTN^G+7XN/NJAD[9[;11^*Q,06X75?OIW</ZDZE85G#7?!6NF!L7V
M&0CE(XULQEC2DUF6>1*YRG69%FZ[%-72C%91,HG(502&$OCWUR+F;QO&1?&S
M)YGCT-G=F_Y2=*EX.Q[)B-^)VV"!'_610`?:.-28()0[Z#H!^[L/C]'T\@"9
M#H2`!X\ZMV+6'4#U>C6KP.`]C]'V?1W]/U\6[<QIRMK31<\C[JKY@\/K^'U_
M=Q"X!L;@FG6-6**@F43"!A`/T``B/W<3K+?+;VD#[:QR.(A=@3ZA<_FK&0D6
MCDZR2"[=95LJ"#I)%PBLHU6%,JOI.")&,9%7TS@/E-T;H0'KH0XI;I)ZQ9=+
M'QOX4Z,B0$J=1Q'AZ_`^BN6WW!L9>X)MUM-DC-FO6`9\]=T4/6H34>TVO(SS
M$[MUF^HSE=RAF7)U8H$C7W:F7ZOD*`9(T)I_CMFCAN5T*)S&4$0Z=V_G=O;/
MMZX.YR)UYWPS?"&LC:*.JX\LJ;,39KV(YWKF6^XG<.[[@V=MZ.L>'K'\?2.H
M:L2MOXEQ<`:6N-=*D_C:\;\;*96V*SS`9#V'UVQAC_&V%+WC/7*[89@4H:[.
M;EK%:I'*.-6R=EIS"Z)WNGYP09B1\WD')&R[?T!:JIN"@%5DXW;FW8>+C@1S
MSREP75_E"S`*Q770Q\M.-6$.1W'GYF7*LAA3'C6R%3\9:,L>DWTLWPWUIIT7
MGN=8ZU=U0R-D'8':&SU//4KABQ[9/ZK@:C63:'5*`'$TS(WR+I%6A:"<[Z#N
M65_EZ#\ZU8D9.KL`.!"+^<QRRO+[;FW">#%A@)QU<Q^;(PCG\-;@JP%ROQV)
MT-N43(G[CQ<#&RLJ2<ID2*)/+0L\`)XZ$]2WXZ"WVHW\[/>`K=`KELKK'..1
MX/--HSSJ?B%:Z8AKM9R728NQ6FMNM7=WLW4IC662E1<Q%?7GVLTDZ19L5FS.
M/678(K+'`9D6W]GS93)DF*,Q11SL(Y&*.;?Q,=22?BX6.MS?A4$[AWB,838H
ME=)9I(1YB]+(OZ$Y&NA_5Y?K&U-/F*,]SO9O"UYQAFV+S:Q1UCR#J5@5Q)5S
M'L8S>[(Y@B-OHB:N.X],*A5W0KU2IX<@(9^@9`OR5)\^>'7;J)H>4DK!3M3:
ML]<G'DC=,F":2Q;^4OEFT+C]9FMKZ-*Q;@_=6YX+0Y2]"X\T*74$L[=>LH\`
M!?34>FG=S9E;W;L9IY(Q=2I?.V1,7X^W6DZ2[V!7Q9%GS6_UV>8-K-TK#R+=
M4+#%PCYVN?FM(O8IY8(>DR*R`()MU"I=G6)#VO$[-S$7,RO)6:7!#!.MNA9%
M<J3\RDL19@"]K$\>-9=QW'NS'+XN/YSQQ9S*7"W=HR`5UM8+R.G&VO`%J]B-
MD_<YB*;'*X;1W0B+I6=<*Q<:Q9Y&G3MXIV9<G'E[2Z>UU*E--(D9PEACB-FS
M&70LB])37*9(S9))/MRK(V[9^UY2'GEQ3&TK*5#%2HZ=&+-(;B^N@)Y$TS-W
MKN:.XAARQ(B!P2"0UC\M@HXZ\3RK'W-F][<]*6BEYJA=JV3L-C-*;)@C"N(]
M>S2>NEHQ+&67"]WOM\R1D^-IECL+&ZUNSJ3:KN-=S41\K/%))B@X3,8>9-HC
MV#`2.3`_".YQ)Q(7D%PW457I!TU&O`Z<^9C;ME[_`)J2QYJY"L,G'*!4(5EM
MU.=.%OEX^/A83B]U'4_*&T^\VA433,:8UN]5K^,=KE;/-9ZQA;<G:_U^5<QU
M`6K3*]1]5FZXJPG9E5FJ$.JH]((+I',5-40$G*'M3==NV[8-P.1*XRWFA"")
ME#D!G+:LK6L+7T]M;#W7M6X[IW%@Q8<:/$()"3*&:(&PL&"E=2;6UK71C-A[
MC>K6LN-,>XFHV:<8L)C:O:&2VSKN/,;6HK#!<DT2@$,4T;7`GY?;#3:6K=M,
M@M)QLS%PDMZ[E<6ZYV/^((['(>U]WWG)DS90P3%B\AW*DN2I+^8+Q`LI`%@?
M3Z*UUG[EVK:X!C1,K29$@G2,/TIT$=`C(#V#`DF]KVMK:GQR9G?W(JU?Z-(P
M]JVORC57%'US^5X?Q5B^[4VZ*RDNTB!R3_..2KOI9(X]M5DE7<@J[<+/G=,2
MC6Z)FJS5JJ43!7X6W]K9>*N-*88<AO-+2NP(/2I*]*K("HTM8WU(J9D[MW3%
MG++$)9,1NE1&`5*7XEF9/C)XW`%J6,?G_P!T!ML3L5^;-.V4.SKD]LA^46&\
M/5Y2%JMIQ]7:99SX3&C6I?6R]X[EK78?0:N4I"5OB'J3`@FHP'RD9K-_R[MC
M_*L<XKXGF2!.IG?523J+>8G#G\/MIIW;NB/=IDR8LLQ(I*A+E3IP^&-AZM;G
MC:F$@=E/=J4I.T,?6G6S\IZ^IU.ON-WMGQ'.S-\Q_G4,X4"`F:C6[!:-8\)L
M)Z:5QM.RBCU@A$33("M#.D7!0()0EY.V]IPG%$GX=I4RV1Q&^CQ^6"&/\22W
MQ&W$&L&)NW=F0,IXDR$B?%5E\SJNC^800MU0GX1<V%ONG/G,N]V!,BXDQQD3
M93<"X:MR59S!<IK8G6_7:DY%SZWO<A:(0N*L,Y)8P..;NT85BM4IR^6+.LJP
MW&5?)E37%#RAYJ'&CV++PYI<>"%=Q26,".26RE+N2R_+?6P()-@+W\;[+EWS
M$RL=,J>9L!X'+/%'=@Y5;*=3X7'#C[0P%-INZ&(LO[$;`86LNS#6,O/N<ZUP
M4CC*QXPA'U.S+@&_8QPG5\DYAM<2_P`?-[I'2D4Q%P+^3BW\7'13N/4(=L02
M*`%A-)L>7BX>%D+`"N#(6=";K('>R7O8Z6U-S4&&'?<:;-S<1YQU;A%TJXT:
M,JO4Q%A:_.VE=0OD^O\`3]?W>(CX<YMY:`:#WZUU#XC\QT]&GO\`&J>3_B'X
M]]CXC]G?%"V:XM;\K^^G7%[D"]7>41#H3#]H>'`KK?TZ7UM3+'IZ23?Q&E-E
MF._#BG%U^R2$6:<&CU>6LGR<KL6'S+Y8T.Y_"'>_AWGX5-;R=&4])3R%['H>
MN,D;R8BZJ"1KZ_'U>O6J;N7>_P#YWM_+WKH$IQH"P4GI!(X78`](N=38V'*H
MC.=URMDH%+\5@$Q9B>N,+_.9<X#^621JE5*E9@C@MJE/11-9Y4;5Z*3$A50*
M5JH<5.Q%,D+\1.+6C1B]SQX`#@2?F/IT]5<JF^K&1!^&Q[;2//DG'G?BW,`6
M&&*0+U>2#YTC2E5BM;X&/5RKRX/>:8E[?CZO)8F6;Q%U88S54EE)R4]&.=Y`
MHJE[=MDI8:VE7CJP#!/HC=9VV=RA0$6R1C`*?$&9,MO+A54'#U6O;A;V??4/
M#^M.XYN;@QR;6XQ\V+')8>999)H3*ZAC$%8)8@:AFXV'"K(O=N_*5*H7"UX;
MB<<UZ_2E'85RYW^]N:O1D`M\#;;$X/,S#^M`X;)Q#.MMR`N5$6[E621(0X&`
MQ1='EY+?-$HOPUMX\[4W;_J[W%F;=B[AN.T1[?C9F1#'')/.ZQ6D5V=F80$K
MT=(`TLW5J17D.]_IA%.HKQ^*F4RTL*:8OI>'MD@^K(N'&7[#BADM%VM*LA!M
MH.7_`)=/(LY&159-%DU2(^;U#$$V+\28V!,.I&ECZ;$$VMKZ=*A2?6_<T.$T
M&VQRID+>5A)*40G,_")Y;&$=2%09>M@O(6YTH7.]Q9*.S.[I^/%'A\6(J6.M
M&M#NS5B.RICYC+'K<O:JE(+TU5LX686$$O*DB+M!2/>M'/KE%;TROCG!C<I%
MTJ+$<5N#>YO;7A_35W+]7LZ7'W5]MV_JR,`-)")S+$,O'64PL\3>2Q#AP3T@
M-="IOK2QNNU\O1+,I3;#`X_K<LTL]2JLE:;7D1Q7<=1CFS8WL&0SN'5B>5L[
M@B9!@@CVQ#($,Y<N"#V7_9&1/D>7*D94W8@#4:$@DZE3X5(WSZG;CL^XILDF
M-AX\YFCC:2>:5<=6?$ERC>58KVNBQJ2NK,>!%B@?_P!^J-*ZQLS[$,TY@I"D
MUF?+9*[-&L5;9V2U7RV4F#@I-RSA22#&"L/\JG=,)L6QF1O6327!`#D4-$CS
MI7($::=(-SKQ)%M`-/352_ULFBVU\V3:<F4?A89.N$.\`DEGDA6,N5!MTQ^9
MUA>!`8:@UL<`!.)@'P\H]!U\!^OZAY:&)"H!L5Y"PT]]Z[WJ=#<,./'7W$<N
M/NJ\"B'^\(^/?C]WT\4*!^0^X"G*+"QU]_WDT>7Q[[Z\`#P\/`.!`/Y:^^DZ
M=;@V^RJ@7H.N^_M_T^'`*H%@``*`I`U))-7<6G4<**.%%)VV?T_*?NCC]@IQ
M1\K?LFHFX?Z9D_X=_LJ*+O\`RSA/[E=_L#<5>*_V?_"N09O^@P?^P_J"GG5_
MAK3]^IW_`*\.8N3?M5ON/_*P/VH?^V:Q;]_EPT^R&_Z./B_O'MJ%OO\`M*'^
MTC^P5YC7^BB?VA'_`/T!^/7^8_KJ!B_Z1'_A%_\`(-*^5_A%?_MAS_RQ/&9'
M\H^L5?9OSP_V#?O+2.RK_"9?]\A?_'6X'^^1^O\`JFJ?OK^[Y/\`TOW6I40?
M]+C_`&O!?MG/(N-\Z_L#[ZLL;_:K^I?WZ=TGP'[1_P!7)(X5MZ\/:?MJ_BTZ
'CA11PHK_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
